Fractalkine as a severity marker of atopic dermatitis in infants and toddlers

Viktoriia Klymenko¹, Oleksandr Ashcheulov¹, Olena Vysotska², Anna Pecherska²

¹Department of Fundamentals of Pediatrics No. 2, Kharkiv National Medical University, Kharkiv, Ukraine
²Department of Biomedical Engineering, Kharkiv National University of Radio Electronics, Kharkiv, Ukraine

ABSTRACT

Introduction: Atopic dermatitis (AD) is a common chronic inflammatory skin disease.

The aim of the study were the relationship determining between level of serum fractalkine and clinical signs of AD; and establishing correlation between the level of serum fractalkine and paraclinical signs of AD (total Ig E level, immunogram value).

Material and methods: 60 children with clinical manifestations of AD in the exacerbation period of the disease (main group) and 16 healthy children without chronic diseases (control group) took part in the clinical study.

Results: The study showed that the serum fractalkine level is elevated in all forms of AD severity: mild – 8.55 (6.11–10.79) ng/ml, moderate – 10.97 (5.61–14.01) ng/ml, severe – 12.53 (9.01–16.68) ng/ml. It was also established that serum fractalkine levels correlate with the overall assessment of the AD severity on the SCORAD scale, total intensity of all lesions, erythema, excoriations, itching and sleep disturbances (p < 0.05). Direct correlation of fractalkine level count with neutrophil count (27 [24–71] p < 0.05), and vice versa – with the number of lymphocytes (61.5 [26–70] p < 0.05) was uncovered when analyzing serum fractalkine levels and paraclinical criteria. The study found a connection between the serum fractalkine levels and immune indicators as well: inter alia the probable reduction of CD3, CD16, Ig G and the probable increase of CD4, CD22, CD25 and Ig E.

Conclusion: Fractalkine can be used as an objective severity marker for acute phase of AD.

KEY WORDS:
children, atopic dermatitis, fractalkine.

INTRODUCTION

Atopic dermatitis (AD) is a common chronic inflammatory skin disease, its prevalence rate among children is approximately 10–20% [1, 2].

Atopic dermatitis was first described in the seventeenth century. By the twentieth century sufficient clinical observations were accumulated and the main clinical signs of AD in the form the widely used today Hanifin-Rajka [3] diagnostic criteria were identified [4]. Further development of immunology allowed investigation of the abnormalities at the cellular level and formulation of the immunological concept of AD: it was proven that in acute lesions first-type helpers predominate, while in case of process chronisation the profile of second-type helpers prevails [5]. The twenty-first century marks a new stage in the study of AD problem at the molecular level: today not only molecules and receptors that mediate cellular interaction are known, but also new therapeutic strategies based on the relation of monoclonal antibodies to target mediators are being created. Thus, in the severe form AD the use of dupilumab – monoclonal antibodies to interleu...
Fractalkine as a severity marker of atopic dermatitis in infants and toddlers

IL-4 and IL-13 is possible [6], while in mild and moderate forms of AD the effectiveness of crisaborole – the inhibitor of phosphodiesterase-4 – has been proven [7]. Thus, the main direction of scientific research in the study of AD at present is the study of individual molecules, receptors, mediators of allergic inflammation.

Among chemokines and chemokine receptors associated with allergic inflammation, elevated levels of CX3CL1 (fractalkine) and its unique receptor (CX3CR1) were detected during AD [8].

Chemokines are peptides that regulate cellular interaction. In the skin chemokines are secreted both by resident cells, such as keratinocytes, melanocytes, fibroblasts, dendritic, mast cells, and other cells that penetrate the skin – lymphocytes, eosinophils, and monocytes. Chemokines are involved in the induction and maintenance of the inflammatory process in the skin and regulate the emergence of cell infiltrates. The accumulation of activated mast cells in the affected areas of the skin forms the skin manifestations of AD.

Fractalkine exists in two forms: cell-bound membrane and soluble. In its membrane-bound form fractalkine acts as a molecule of adhesion, whereas in its soluble form it acts as chemoattractant for T-cells, NK-cells, and monocytes. Recent studies have shown that fractalkine is expressed on cells of the monocyte-macrophage series, which in turn contributes to the circulation of dendritic cells through the inflamed lymphatic vessels [9].

The importance of fractalkine was noted in many inflammatory diseases, including rheumatoid arthritis, vasculitis, systemic sclerosis, and others [10, 11]. Therefore, fractalkine can be considered as a potential biomarker for assessing the severity of the disease in patients with allergic diseases. Therapeutic interventions for AD in children aimed at fractalkine deserve further scientific research.

AIM OF THE STUDY

The aim of the study is to determine the relationship between level of serum fractalkine and clinical signs of AD; to establish the correlation between the level of serum fractalkine and paraclinical signs of AD (total IgE level, immunogram value).

MATERIAL AND METHODS

The research was carried out on the basis of the Department of Children of Younger Age the Regional Children’s Allergological Centre and the Consultation Clinic of Kharkiv Regional Clinical Children Hospital No. 1. The study involved 60 children with clinical manifestations of AD in the exacerbation period of the disease (main group) and 16 healthy children without chronic diseases (control group).

The patients selected for examination were children aged from 29 days to 3 years with clinical manifestations of AD. Patients with complications of AD (bacterial or fungal skin infections, lymphadenitis, etc.), congenital defects, other chronic diseases, any acute illness or lack of compliance with parents were excluded from participation in the study.

In addition to traditional clinical-paraclinical examination, the study included an assessment of AD severity based on the scoring of atopic dermatitis index (SCORAD), the determination of immunological parameters (CD3, CD4, CD8, CD16, CD22, CD25, IgA, IgM, IgG) and total IgE level.

The determination of fractalkine levels was performed by enzyme-linked immunosorbent assay using human fractalkine ELISA reagents manufactured by RayBiotech Inc., USA.

This study was performed according to the ethical principles of the Declaration of Helsinki and the ethical norms and orders of the Ministry of Health of Ukraine. After explaining the aim and methods of the study, written informed consent was taken from parents of all participants.

The statistical software StatSoft STATISTICA version 7.0 for Windows was used for statistical analysis. The Mann-Whitney U test was used for abnormally distributed continuous variables, and data were presented as medians and interquartile ranges. A p-level of less than 0.05 was considered significant.

RESULTS

Sixty children were examined: 63% boys and 37% girls. The division of groups is shown in Table 1.

<table>
<thead>
<tr>
<th>Age</th>
<th>From 1 month to 1 year</th>
<th>From 1 year to 2 years</th>
<th>From 2 years to 3 years</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>Boys</td>
<td>Girls</td>
<td>Boys</td>
<td>Girls</td>
</tr>
<tr>
<td>Severity</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mild</td>
<td>4</td>
<td>3</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>Moderate</td>
<td>3</td>
<td>5</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Severe</td>
<td>3</td>
<td>1</td>
<td>13</td>
<td>2</td>
</tr>
<tr>
<td>Total</td>
<td>10</td>
<td>9</td>
<td>20</td>
<td>1</td>
</tr>
</tbody>
</table>

19 25 16
TABLE 2. The level of serum fractalkine in patients depending on the presence of asphyxia

<table>
<thead>
<tr>
<th>Assessment of the child’s condition in the first minute, % of children</th>
<th>The level of fractalkine, ng/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal index on the Apgar scale</td>
<td>11.66 (8.27–14.38)*</td>
</tr>
<tr>
<td>Children with asphyxia</td>
<td>6.84 (5.59–11.11)*</td>
</tr>
</tbody>
</table>

*p < 0.05

All children were suffering from AD and were divided according to AD severity (depending on the SCORAD index): mild – 27%, moderate – 35%, and severe cases – 38%.

Regarding the features of the AD course it should be noted that in 38% of the children’s lesions were of limited character, while 62% had widespread manifestations. However, the severity of morphological lesions (the total score of all morphological elements on the SCORAD scale) was insignificantly mild – only in 17% of children was the intensity index more than 10 points. The subjective component was the most difficult one to evaluate because infants and toddlers usually do not experience itching, so it is hard to determine the cause of sleep disturbances and the connection of the above with AD exacerbation. However, 23% of patients suffered from itching rated up to 5 points and 77% of the patients rated more than 5 points. Sleep disturbances occurred in 63% of the cases.

From the anamnesis of the disease, it is known that the first clinical manifestations of AD are detected on average starting from the age of 4 months, namely 51% – until 3 months, 33% – from 3 to 6 months, 16% – from 6 months to 1 year. The course of the disease is characterised by frequent exacerbations, in particular: 41% – more than 6 times per year, 30% – 4–6 exacerbations, and 29% – less than 2. During treatment the majority of patients used moisturising agents (86%), topical glucocorticoids (43%), and antihistamines (74%).

It is known from the patients’ life history that half of the mothers (51%) had normal pregnancy, 18% had over-vomiting during the pregnancy period, 12% had the threat of preterm delivery, 11% had placental insufficiency, and 8% of the pregnant women had anaemia. Only 20% of the mothers followed a hypoallergenic diet during pregnancy.

Most of the deliveries (97%) were on time, 2% were pre-term, and 1% were post-term. In 73% of cases the delivery was physiological, and in 27% it was by C-section. Nineteen per cent of the children were born in asphyxia. The level of serum fractalkine was significantly lower among children born in asphyxia (Table 2).

As a result of the study, a link was established between the severity of AD clinical manifestations and the serum fractalkine level (Table 3).

TABLE 3. The level of serum fractalkine in children, depending on the severity of AD

<table>
<thead>
<tr>
<th>The severity of AD</th>
<th>Fractalkine, ng/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild (n = 16)</td>
<td>8.55 (6.11–10.79)*</td>
</tr>
<tr>
<td>Moderate (n = 21)</td>
<td>10.97 (5.61–14.01)*</td>
</tr>
<tr>
<td>Severe (n = 23)</td>
<td>12.53 (9.01–16.68)*</td>
</tr>
<tr>
<td>Control group (n = 16)</td>
<td>4.29 (3.52–5.27)*</td>
</tr>
</tbody>
</table>

*p < 0.01 compared to severe AD, †p < 0.01 compared to the norm, ‡p < 0.001 compared to the norm

DISCUSSION

In modern literature fractalkine is considered as a multifactorial marker. It is studied not only with AD, but also with asthma, allergic rhinitis, and other autoimmune diseases. It is confirmed by the scarcity of works of fractalkine binding with AD in general, and in particular in young children.

Many works have described in the experiment on the model (mouse) that the value of fractalkine is shown, ...
Fractalkine as a severity marker of atopic dermatitis in infants and toddlers

but the characteristics of the reception vary in humans and mice. In humans, CX3CR1 has two known ligands: CX3CL1 and CCL26 (eotaxin-3). In mice, the CCL26 gene is however a pseudogene, and CX3CL1 is therefore the only known ligand of CX3CR1 [12].

It is important to clarify the meaning of fractalkine in humans. The serum fractalkine is elevated only in some people with AD. In AD patients, CX3CL1 is up-regulated in both endothelial cells and skin lesions, and serum CX3CL1 levels are positively associated with disease severity [13]. Another study reported that, although CX3CR1 mRNA expression is consistently up-regulated in AD skin, CX3CL1 mRNA levels are only increased in some patients with a significant correlation to the disease severity [14].

The study of this topic is important not only for a scientific purposes, but also for the search for a new targeted treatment of AD. Although inhaled corticosteroids are very effective as an anti-inflammatory treatment for persistent asthma, they do not cure asthma. Furthermore, 10% of asthmatic patients do not respond to this treatment [15]. More specific therapeutic agents such as antibodies to IL-5 have been tested in clinical trials, but the results have been rather disappointing [16]. The same studies are needed for the role of fractalkine in AD.

**CONCLUSIONS**

The level of serum fractalkine is elevated in all forms of AD severity and correlates with the overall assessment of the severity of AD on the SCORAD scale, the total intensity of all lesions, erythema, excoriations, itching and sleep disturbances. There are established correlation bonds to the level of fractalkine: positive – with the number of neutrophils, CD8 lymphocytes, stimulated neutrophil activation index, and lysosomal-cationic proteins; negative – with the number of lymphocytes. The level of serum fractalkine can be used as an objective severity marker for acute phase of AD.

**DISCLOSURE**

The authors declare no conflict of interest.
REFERENCES


